Off goes DNA. The stock tumbled down today. Lets find out what's happening:

Shares of Ginkgo Bioworks Holdings Inc - Class A (DNA) are trading -5% lower at a price of $2.635 at the time of this writing.

Ginkgo Bioworks Holdings Inc - Class A has been trading between a 52-week high of $15.86 and a 52-week low of $2.09. The stock has a market cap of $2.88 Billion.

Acquiring Zymergen (ZY) in an all-stock transaction worth approximately $300M
Just over a year after Zymergen’s April 2021 IPO
Zymergen (ZY) shareholders will receive 0.9179 Ginkgo shares for each Zymergen share, implying ~5.25% pro forma ownership of Ginkgo post-deal
Transaction represents Ginkgo's largest acquisition to date
Ginkgo Co-founder and CEO Jason Kelly: “We have always had incredible respect for the Zymergen team and the strength of the technologies that they have built for cell programming"
Deal expected to close 1Q 2023

Ginkgo Bioworks is building a platform to enable customers to program cells as easily as they can program computers. The company's cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals.

Headlines

Zymergen Stock: Upcoming Ginkgo Bioworks Acquisition (NASDAQ:ZY)
Seeking Alpha 07-26-22

Cathie Wood Loaded Up on Zymergen (ZY) Stock Before Ginkgo Buyout
InvestorPlace 07-25-22

Ginkgo Bioworks acquires competitor for $300M
Business Journals 07-25-22

Ginkgo Bioworks Expands Horizontal Synthetic Biology Platform With This Stock Deal
Benzinga 07-25-22

Zymergen (ZY) Stock Soars 20% on Acquisition News
InvestorPlace 07-25-22

Off goes DNA. The stock tumbled down today. Lets find out what's happening:

Headlines

Recommended Articles